Regulatory considerations for 3‑D‑printed pharmaceutical excipients under the EU MDR

What regulatory framework governs 3‑D‑printed pharmaceutical excipients under the EU MDR?

The EU Medical Devices Regulation (Regulation (EU) 2017/745) applies to any substance that forms an integral part of a medical device, including excipients produced by additive manufacturing. When an excipient is incorporated into a drug‑device combination that is classified as a medical device, the MDR supersedes the previous Medical Devices Directive. The regulation defines three main routes for compliance: classification, conformity assessment, and post‑market surveillance. For 3‑D‑printed excipients, the classification depends on the intended use and the risk posed by the material, as outlined in Annex VIII. Most solid oral dosage forms fall under Class I (low risk) if they are non‑invasive, but devices that deliver the drug via a novel route (e.g., inhalation or transdermal) may be classified as Class IIa or higher, triggering more stringent assessment.

How does the classification of 3‑D‑printed excipients affect the conformity assessment process?

Classification determines which conformity assessment route is required. For Class I devices (including many simple oral dosage forms), the manufacturer can self‑declare conformity, provided a Declaration of Conformity and a technical file are maintained. However, if the excipient is part of a Class IIa, IIb or III device, a Notified Body must be involved. As of 2024, there are 23 Notified Bodies designated for MDR assessments across the EU, each with specific competence in additive manufacturing. The technical documentation must include:

• Detailed description of the 3‑D‑printing process (e.g., fused‑filament fabrication, stereolithography).
• Material safety data, including toxicological evaluation according to ISO 10993‑1.
• Validation of the printing parameters (layer height, laser power, post‑cure conditions) and their impact on residual monomer or catalyst levels.
• Evidence of compliance with the General Safety and Performance Requirements (GSPR) in Annex I, particularly sections on biocompatibility and sterility where applicable.

The involvement of a Notified Body adds a review of the Quality Management System (QMS) – typically ISO 13485 – and an audit of the manufacturing site. For 3‑D‑printed excipients, the QMS must cover digital file control, versioning, and traceability of each printed batch.

What specific material and manufacturing controls are required for 3‑D‑printed excipients?

The MDR does not prescribe exact material specifications, but it requires that any material used in a medical device be demonstrably safe. For polymeric excipients, manufacturers must provide:

• A Certificate of Analysis (CoA) for the raw polymer, confirming compliance with pharmacopeial standards such as USP or EP where applicable.
• Results of analytical testing (e.g., HPLC, GC‑MS) to quantify residual solvents, monomers, or photoinitiators. The European Pharmacopoeia sets limits for many common solvents (e.g., ≤ 5000 ppm for ethanol).
• Biocompatibility testing according to ISO 10993‑5 (cytotoxicity) and ISO 10993‑10 (irritation/sensitisation). For devices that contact mucosal surfaces, ISO 10993‑12 (sample preparation) is also relevant.
• Process validation data showing reproducibility of critical parameters such as melt temperature, extrusion speed, and post‑processing UV cure dose. Typical acceptance criteria include a coefficient of variation (CV) of ≤ 2 % for printed dimensions and ≤ 0.5 % for residual monomer content.

In addition, the MDR requires a robust post‑market surveillance (PMS) plan. For 3‑D‑printed excipients, this includes monitoring of batch‑to‑batch variability, reporting of any adverse events linked to the excipient, and periodic re‑evaluation of the material safety dossier.

How does the EU MDR interact with other regulations such as REACH and the EU Cosmetics Regulation?

While the MDR governs the device aspect, the material itself remains subject to REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals). Any polymer or additive used in the printing process must be registered under REACH, and the safety data sheet (SDS) must reflect the intended medical use. If a substance is listed on the REACH Candidate List of substances of very high concern (SVHC), its use may be restricted unless a specific exemption is granted.

For excipients that could also be used in cosmetic products, the EU Cosmetics Regulation (Regulation (EC) No 1223/2009) applies. However, when the same material is used in a medical device, the MDR takes precedence for that specific application. Manufacturers must therefore maintain separate dossiers: one for the medical device (MDR) and another for any non‑medical uses (REACH, cosmetics).

What are the post‑market obligations for manufacturers of 3‑D‑printed excipients?

After a device containing a 3‑D‑printed excipient is placed on the market, the manufacturer must:

1. Maintain a Post‑Market Surveillance (PMS) system – collect and analyse data on device performance, including any incidents related to the excipient.
2. Submit Periodic Safety Update Reports (PSURs) – for Class IIa and higher devices, a PSUR is required at least annually, summarising safety data and any corrective actions.
3. Implement a Vigilance system – report serious incidents to the competent authority within 15 days, as stipulated in Article 87 of the MDR.
4. Update the Technical Documentation – any change in the printing process, material supplier, or design must be reflected in the technical file and, where applicable, re‑assessed by the Notified Body.
5. Conduct Trend Reporting – aggregate data on minor incidents to identify emerging risks, a requirement introduced in the MDR amendment of 2022.

Molekula, as a supplier of high‑purity polymers and custom‑printing services, assists customers in establishing the necessary documentation and quality controls to meet these obligations, without acting as a marketing conduit.

Frequently asked

Q1: Does a 3‑D‑printed excipient always need a Notified Body? A1: Only if the final device is classified above Class I. For low‑risk oral dosage forms, the manufacturer can self‑declare conformity, provided all technical documentation is complete.

Q2: How long does the conformity assessment take for a Class IIa device? A2: The timeline varies, but typical assessments by a Notified Body range from 6 to 12 months, depending on the completeness of the technical file and the QMS audit schedule.

Q3: Are there specific limits for residual monomers in printed polymers? A3: Limits are set by the relevant pharmacopeia or REACH. For many common monomers, the EU limit is 0.1 % (w/w), but manufacturers must verify the applicable threshold for each material.

Q4: Can a single excipient be used in both medical devices and cosmetics? A4: Yes, but separate regulatory dossiers are required. The MDR governs the medical‑device use, while REACH and the Cosmetics Regulation apply to non‑medical applications.